Method for bone defect plasty

FIELD: medicine.

SUBSTANCE: what is applied is a stocking coating of an autogenous bone with a patient's platelet-rich plasma. Bone marrow aspirate from the patient's ilium and/or mesenchymal stromal cell autoculture prepared of the aspirate by culturing in vitro are injected under the coating layer into the autogenous bones. The autogenous bones are placed tightly in the bone defect to cover the defect area with adjacent soft tissues.

EFFECT: complete and effective synthesis of the bone tissue continuity by creating conditions of proliferative process isolation and osteoresorption process deceleration in the autogenous bone with no undesired immunological responses in the plasty area.

1 dwg, 1 ex

 

The invention relates to medicine. Can be used in Oncology, traumatology, orthopedics, General surgery.

The known method plasticity of bone defects by the application of allograft - biocomposite material Callahan and platelet-rich autoplasma for the treatment of non-consolidation of fractures, false joints and bone defects (1).

The disadvantage of this method is the use of alien biocomposite material is the possibility of immune reactions and transplant rejection.

The known method plasticity of bone defects with autologous bone grafts taken from the standard donor area of the patient (2).

The disadvantage of this method is long-term reconstruction grafts, there lysis grafts without osseous defect of the newly formed bone tissue. This method is used for the prototype.

The purpose of the invention is to achieve full and effective restoration of the integrity of bone tissue in the replacement of defects of its own tissues and cells of the patient with the lack of immune response, without the possibility of rejection and long-term realignment of the bone autotransplants.

This goal is achieved by the fact that bone autotransplants cover type "stocking" layer of platelet-rich autoplasma patient; below this layer in the bone is autotransplanted injected punctate bone marrow from the iliac bone of the patient and/or received from punctate by in vitro cultivation of autoculture mesenchymal stromal cells; tightly place the bone autotransplants in the bone defect, covering the area of the defect adjacent soft tissues.

The way plastic bone defects is illustrated by figure 1, which shows a bone (1) defect (2), in which is placed the bone autotransplants (3), covered by type "stocking" layer (4) platelet-rich autoplasma patient. Under layer (4) platelet-rich autoplasma patient injected punctate bone marrow and/or received from punctate by in vitro cultivation of autoculture mesenchymal stromal cells (5). The area of the defect (2) bone (1) is covered by soft tissues (6).

The method is implemented as follows.

The bone defect resulting from violations of regeneration processes, diseases, bone resections, prepare to host bone autotransplants, assessing their shape, size and quantity. Perform bone autotransplants of the standard donor areas. Receive platelet-rich autoplaza patient. Every bone autograft cover type "stocking" layer of platelet-rich autoplasma patient. Make puncture of the wing of the Ilium of the patient. It punctate bone marrow of the patient. With the purpose of obtaining autoculture mesenchymal stromal cells punctate bone marrow cultured in vitro. Under the LOI platelet-rich autoplasma patient, covering the bone autotransplants, injected punctate bone marrow from the iliac bone of the patient and/or autoculture mesenchymal stromal cells. Bone autotransplants tightly placed in the bone defect and cover the adjacent soft tissues.

The way plastic bone defects is illustrated by a clinical example.

Clinical example

Patient A., aged 27, was admitted in the Department of adult Orthopaedics Clinics Samara state medical University, diagnosed with Fibrous dysplasia of the upper third of the right tibia. The patient was performed an operation to remove a lesion fibrous dysplasia, and then in the right tibia was formed defect. Made of plastic bone defect on the proposed method. One of the standard donor areas - wing of the Ilium of the patient were taken two bone autograft, Every bone autograft was surrounded by the type of "stocking" layer previously received platelet-rich autoplasma patient. Was made to puncture the wing of the Ilium of the patient. The resulting punctate bone marrow was injected under a layer of platelet-rich autoplasma bone autotransplants. Bone autotransplants were firmly placed in the defect of the right tibia and covered with soft tissue. The wound was sutured in layers. Right lower con the durability of the patient was immobilized with a plaster Longuet from the fingertips to the upper third of the thigh. Control radiographs in the postoperative period was noted by the substitution zone plastics bone defect of the right tibia of the newly formed bone tissue. The support function of the limb was completely restored. Relapse of the underlying disease in a patient not subsequently observed.

The way plastic bone defects can be widely applied in traumatology, orthopedics, Oncology, General surgery. He has such undeniable advantages to use your own autological of the patient's material for plastic bone defects. Moreover, autologous materials during replacement of bone defects are not only bone autotransplants derived from the standard donor areas, but also enriched platelet autoplasma patient and punctate bone marrow and/or received from him autoculture mesenchymal stromal cells of the patient. The use of native materials for bone tissue substitution ensures no unwanted immune reactions in the area of plastics. The use of autoclear effectively stimulates the regeneration of bone tissue.

SOURCES of INFORMATION

1. RF patent for the invention №2356508 "Method of treatment of non-consolidation of fractures, false joints and bone defects in long bones. / Mironov S. p., Kesan GA, Berchenko GN. andetc. // Bul. No. 15, 2009.

2. Iasconsole. Operative Orthopaedics. -M., 2006.

The way plastic bone defects by replacement of bone autografts was measured from a standard donor zones, characterized in that the bone autotransplants cover type "stocking" layer of platelet-rich autoplasma patient; below this layer in the bone autotransplants injected punctate bone marrow from the iliac bone of the patient and/or received from punctate by in vitro cultivation of autoculture mesenchymal stromal cells; tightly place the bone autotransplants in the bone defect, covering the area of the defect adjacent soft tissues.



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to medicine and specifically to trauma surgery and orthopaedics, and can be sued for surgical treatment of ununited fractures and false joints of cylindrical bones when there is a shortage of soft tissue. The method involves, 5-6 days before an operation, performing needle biopsy of bone and soft tissue fragments from the damage centre of the cylindrical bone and determining presence and nature of obligate intracellular viral infection (OIVI). Super-selective angiographic analysis of the microvascular channel to the capillary link is also performed. Valtrex is administered to the patient 2-4 days before the operation in a dose of 500 mg twice a day. Further, the method involves performing osteosynthesis or re-osteosynthesis with resection of the ends of bone fragments, opening marrowy canals, bone stimulation and batting the space of the bone defect with a gel-like nanostructured composite implant. In the presence of OIVI, resection of bone fragments is carried out in a larger volume until the onset of "pinpoint bleeding", i.e. to areas with satisfactory intrabone blood supply. The composite implant contains thrombocyte-rich autoplasma, mixed in ratio of 1:(1-2) with granules of a complex alloplastic preparation (CAP) based on hydroxyapatite which contains 50-60 wt % collagen. The composite implant also contains either 0.08-2.8 wt % colloidal solution of nanoparticles of zero-valent silver metal Ag0, or gold Au0, or copper Cu0, or palladium Pd0, or platinum Pt0, or 5-12 wt % nanoparticles of said metals in dry form. The nanoparticles have size of 2-40 nm. A colloidal solution of said nanoparticles or colloidal nanoparticles of said metals in dry form is added to the CAP granules. Further, the prepared granules of the gel-like complex alloplastic preparation are laid in a selected ratio on the layer of thrombocyte-rich autoplasma, without mixing, for subsequent transfer into the bone defect space. In case of performing resection of bone fragments in a larger volume until the onset of "pinpoint bleeding", corticotomy is further performed on the cylindrical bone being operated on, with subsequent distraction of the bone regenerate using any existing method. Further, the bone fragments are repositioned, followed by metallo-osteosynthesis. Before wound suturing, the surface of the area with shortage of soft tissue in the projection of the ununited fracture and false joints is covered by a semi-permeable flexible plate made of the complex alloplastic preparation based on hydroxyapatite, which contains 50-60 wt % collagen. The plate has thickness of 0.25-1.2 mm. The surface area of the plate is 10-20% greater than the area with shortage of soft tissue in the corresponding projection. The part of the erythrocyte mass remaining from preparing the thrombocyte-rich autoplasma and the plasma are returned into the bloodstream of the patient by intravenously using a drip during the surgical procedure or in the early post-operation period. After the operation, valtrex is administered to the patient in a dose of 500 gm once a day for two weeks and then in a dose of 500 mg every other day for two weeks.

EFFECT: method provides reliable prevention of OIVI at a damage centre, normalisation of local microcirculation of blood, avoiding ischemic processes, and compensation for the shortening of the length of the limb of the patient being operated on while preventing weakening of the process of reparative osteogenesis and allergic reactions of the body.

6 cl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology, specifically PTH receptor agonists, and can be used in medicine. A polypeptide of formula PTH(1-X)/PTHrP(Y-36) is constructed, where denotes an integer between 11 and 18, and Y=X+1, where PTH(1-X) is an amino acid from 1 to X of the human PTH sequence (SEQ ID NO:5) and PTHrP(Y-36) is an amino acid from Y to 36 of the human PTHrP sequence (SEQ ID NO:6). The polypeptide contains one or more of the following mutations in the PTH(1-X) sequence: Ala in position 1, Ala or Aib in position 3, Gin in position 10, Arg or homoarginine in position 11, Ala in position 12, and Trp in position 14. The obtained polypeptide is used to repair fractures, treat hypoparathyroidism, hyperphosphatemia, tumoral calcinosis, osteoporosis, osteomalacia, arthritis, thrombocytopenia, as well as increase stem cell mobilisation in a subject.

EFFECT: invention enables to obtain a polypeptide having prolonged activity on the PTH receptor.

18 cl, 37 dwg, 8 tbl, 11 ex

FIELD: chemistry.

SUBSTANCE: biocompatible, biodegradable porous composite material contains chitosan and hydrosilicate filler in amount of 0.05-10% of the weight of chitosan and has a system of through pores with size of 5-1000 mcm. The method of producing the material involves mixing hydrosilicate filler, which is pre-dispersed in an aqueous medium with pH=5-7 in an ultrasonic field with frequency v=20-100 kHz for 5-60 minutes, with chitosan in an amount which corresponds to its concentration in the solution of 1-4 wt %, the amount of the filler being equal to 0.05-10% of the weight of chitosan; the obtained mixture is then intensely mixed at temperature of 20-50°C for 20-60 minutes; concentrated acetic acid is added in an amount which enables to obtain, in the mixture of the aqueous solution, acetic acid with concentration of 1-3%; the mixture is intensely mixed at temperature of 20-50°C for 20-250 minutes and then cooled to temperature of -5 to -196°C; the solvent is removed in a vacuum; the obtained end material is treated with a neutralising agent, washed with water to pH=5-7 and then dried.

EFFECT: presence of a system of through pores and providing a stable porous structure of the material in aqueous medium, eliminating cytotoxicity.

6 cl, 9 ex, 6 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to compounds of formula (I) where values of substituents are given in description, possessing inhibiting activity with respect to cathepsin K as well as to pharmaceutical compositions for treating diseases, associated with cysteine protease activity and to methods of inhibiting cathepsin K in mammals, requiring such treatment by introduction of efficient amount of compound to mammal.

EFFECT: claimed is application of formula (I) compound or its pharmaceutically acceptable salt in manufacturing medication for application in cathepsin K inhibition in a warm-blooded animal.

10 cl, 45 ex, 5 dwg

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, namely to oncology, and can be used for treatment of subject's bone tumour. For this purpose bone tumour in subject is, at least, partially ablated. Area, adjacent to the bone section, where tumour was, at least, partially ablated, is brought into contact with gel, containing taurolidine, taurultam, their mixture or their solution, which is in equilibrium. Also claimed is prevention of development of bone tumour recurrence in subject.

EFFECT: group of inventions ensures treatment and prevention of osteosarcoma in subject due to application of gel of suggested medications.

40 cl, 12 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to compounds of formula (l) and their pharmaceutically acceptable salts wherein X represents CH or N; one of R1 and R2 represents H and the other one is specified in OR6, SR6, Me, Et and SOR8; R3 is specified in tert-butylmethyl, sec-butyl, tert-butyl, cyclopentyl and cyclohexyl; R4 cyclopentyl C1-8alkyl optionally substituted by one C1-6alkoxy group; or C3-8cycloalkyl optionally substituted by one C1-6alkoxy group; R6 represents C1-8alkyl; and R8 represents C1-8alkyl, as well as to based pharmaceutical compositions and applying them as cathepsin K inhibitors and for analysing the cathepsin K inhibitors specified above.

EFFECT: there are presented new biologically active compounds and using them in medicine and pharmaceutics.

12 cl, 79 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to a pharmaceutical composition effective for injections in the form of a water suspension for prolonged release of a bisphosphonate agent. Said pharmaceutical composition contains a combined dispersion complex containing a salt of a bisphosphonate agent and a salt of pentavalent phosphorus oxoacid, and the complex has solubility in physiologic saline less than 0.05 wt % at bisphosphonic acid. The invention also refers to a pharmaceutical composition effective for injection which contains the combined dispersion complex containing a calcium salt in the amount less than 50 wt %, a calcium salt of pentavalent phosphorus oxoacid with the solid substance having an average particle size 1-100 mcm, the calcium to phosphorus mass relation is equal to 0.5-3; and the composition has pH equal to 6-9.5 if the complex is suspended in an aqueous medium. The invention also refers to a method of treating or preventing of bone diseases in patients with, e.g. osteoporosis, implying the intramuscular introduction of said compositions in a patient's body.

EFFECT: invention aims at preparing the composition low soluble in the physiological medium and provides prolonged slow release of the bisphosphonate agents.

24 cl, 8 tbl, 3 dwg, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to azabenzofuranyl compounds of formula I and salts thereof, where: Z1 denotes CR1, Z2 denotes N, Z3 denotes CR3, Z4 denotes CR4, R1, R3 and R4 are independently selected from H, halogen, CN, -(CR14R15)nC(=Y)OR11, - (CR14R15)nOR11, C1-C12 alkyl; W denotes or R5 and R6 are independently selected from H or C1-C12 alkyl; X1 is selected from R11, -OR11 and -S(O)2R11; if X1 denotes R11 or -OR11 from X1 and -R5 optionally taken together with a nitrogen atom with which they are bonded form a 4-6-member saturated or unsaturated ring containing 0-2 additional heteroatoms selected from O, S, where said ring is optionally substituted with one or more groups selected from oxo, -(CR19R20)nNR16R17, -(CR19R20)nOR16, (CR19R20)nS(O)2R16 and R21; X is selected from aryl, where said aryl is optionally substituted with one or more groups selected from halogen, CN, -Si(C1-C6alkyl), -(CR19R20)nOR16, -(CR19R20)nSR16, C1-C12alkyl; R11, R12 and R13 independently denote H, C1-C12alkyl, aryl, azetidine, pyrrolidinyl, piperidinyl, tetrahydropyranyl; R14 and R15 are independently selected from H or C1-C12 alkyl; n is independently selected from 0, 1; Y independently denotes O; where each of said alkyl, alkenyl, aryl and heteroaryl from R1, R2, R3, R4, R5, R6, X1, X2, R11, R12, R13, R14 and R15 is independently and optionally substituted with one or more groups independently selected from -(CR19R20)nC(=Y')OR16, -(CR19R20)nNR16R17, -(CR19R20)nOR16, -(CR19R20)nNR16C(=Y')R17, -(CR19R20)nNR16C(=Y')OR17, - (CR19R20)nNR17SO2R16 and R21; each R16, R17 independently denotes H, C1-C12 alkyl, C2-C8alkenyl, aryl, or pyridinyl, where said alkyl, alkenyl or aryl is optionally substituted with one or more groups selected from -OH; R19 and R20 are independently selected from H, C1-C12 alkyl; R21 denotes C1-C12 alkyl, aryl, imidazolyl, pyridinyl, pyrazolyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, piperidinyl, or 2,2-dimethyl-1,3-dioxolanyl; each Y' independently denotes O. The invention also relates to specific compounds, a pharmaceutical composition based on the disclosed compounds, a method of inhibiting anomalous cell growth or a method of treating hyperproliferative disorders, inflammatory diseases and other diseases.

EFFECT: novel azabenzofuranyl derivatives which can be used in treating cancer and inflammatory diseases are obtained.

23 cl, 3 tbl, 34 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular, to traumatology and arthrology, and can be used for non-surgical treatment of aseptic necrosis of femoral head. Method includes performing injections of 2-4 ml of into intra-articular fissure of hip hoint under ultrasonic control. Injections are made in courses 2-5 times per week. Course duration is not shorter than two weeks.

EFFECT: in quite short terms method results in partial or complete recovery of bone tissue structure, reduction of size of necrosis nodules.

5 cl, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to traumatology, and concerns treating long bone fractures in iodine deficiency diseases. That is ensured by introduction of 1 % ATP sodium salt, Iodomarin 200 1 tablet once a day, the preparation "Sea Calcium" with vitamin D3 2 tablets 3 times a day from the first day of treatment, and on the 14th day after reduction and stabilisation, the preparation Chondrolone 1.0 ml is injected intramuscularly once a day for 3-4 weeks.

EFFECT: drug-induced complex provides higher clinical effectiveness due to intensifying metabolic processes and osteogenesis in the given group of patients.

1 ex, 4 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine, and concerns a method for cardiac function recovery following acute myocardial infarction with infarction involvement, wherein the method involves introducing into an individual a non-swelling, recovered population of autogenous mononuclear cells enriched with CD34+ cells containing a subpopulation, at least 0.5×106 of high-active CD34+ cells expressing XCR-4 possessing CXCR-4 mediated chemotactic activity and shifting in response to SDF-1; using the pharmaceutical composition for preparing a therapeutic agent for the cardiac function recovery in the individual after acute myocardial infarction with an infarction inflammation, wherein the pharmaceutical composition contains the above recovered population of the autogenous mononuclear cells.

EFFECT: group of inventions provides less infarction involvements due to preventing cardiomyocyte loss following acute myocardial infarction by improving perfusion and preventing apoptosis.

78 cl, 13 ex, 4 dwg, 36 tbl

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to transplantology, and may be used for treating graft-versus-host disease (GVHD). That is ensured by introducing pluripotent cells, other than embryo stem cells, embryo germ-line cells, germ-line cells into an individual. The cells may differentiate in one cell type of any of at least two embyo lines - endodermal, ectodermal and mesodermal. The cells express telomerase; they are allogenic for the individual and promote the negative immune response. The group of inventions also refers to the above cells which are grown and processed during 10 to 40 cycles of cell duplication in a culture, and then specific markers (oct-3/4, rex-1 and rox-1) are expressed.

EFFECT: method enables using the pluripotent mature precursor cells additionally for immune suppression for transplantation.

21 cl, 10 dwg, 12 ex

Immunomodulator // 2497514

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, and represents an immunomodulator for treating chronic hepatitis, hepatic cancer, lymphatic sarcoma, chronic leukemia, and for improving the functions of liver and blood-forming organs, for enhancing the immunobiological body characteristics, prepared by mixing 1000 ml of an aqueous infusion of sandy everlasting blossom, pepper mint herb and chicory herb with 50 ml of bovine serum containing leukaemia oncovirus antibodies, 20 ml of wild rosemary infusion, 40 g of ascorbic acid, 2 g of sorbic acid, 0.2 g of folic acid until the ingredients are dissolved completely, with adding 60 g of liver powder, 30 g of lymphatic node powder, 30 g of young bovine spleen powder; the prepared solution is settled at room temperature for 24 hours, then kept at a boiling water bath for 30 minutes and cooled for 6-8 hours at room temperature; the settled solution is filtered, wherein the aqueous herbal solution is prepared by mixing equal proportions of the separately prepared aqueous infusions of 40 g of pepper mint herb in 1000 ml of water, 30 g of sandy everlasting blossom in 1000 ml of water and 30 g of chicory herb in 1000 ml of water, while the wild rosemary infusion is prepared by infusing 60 g of ground wild rosemary blossom in 1000 ml of 70% purified ethanol.

EFFECT: invention provides creating the high-efficacy agent and reducing the length of treatment.

FIELD: biotechnologies.

SUBSTANCE: method is proposed to extract stem cells, including whirling of heparinised bone marrow with hydroxyethyl starch at the ratio of source ingredients of 1:2 with speed of 700g for 15 min. in the closed system of three haematological containers connected to each other with tubes with subsequent removal of fat admixtures and plasma into the container No.1, transfer of the mononuclear fraction of bone marrow, a part of supernatant and erythrocytes adjoining the interface of two media into the container No.2. Sludged erythrocytes and bone fragments remain in the main container, whirling of the produced sample with the speed of 900g for 15 min. in the container No.2 to produce cell material for intravascular introduction, at the same time after the specified whirling a part of supernatant is removed into the container No.1 without unsealing of the system.

EFFECT: production of paracrine effect of bone marrow mononuclear cells and provision of safety.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine. A method for preparing a biomaterial, which provides bone tissue regeneration, contains biphasic calcium phosphate (BCP) in the form of granules homogeneously dispersed in a three-dimensional blood protein mesh or bone marrow protein mesh, including the following steps: (i) mixing biphasic calcium phosphate in the form of granules of 40 to 500 mcm with blood or bone marrow aspirate in ratio 10 to 90 wt % of BCP of blood or bone marrow volume, g/ml; (ii) adding at least one coagulant to the mixture prepared at the stage (I) in an amount adequate to cause blood or bone marrow coagulation. The biomaterial further contains one additive specified in polymers, ceramics particles, pharmaceutical compounds, natural or synthetic growth factors, biomarkers, contrast agents, tissue or cell preparations. The kit for implementing the method comprises (a) a device having an internal sterile container with BCP; (b) a sterile container with a coagulant. The biomaterial is used in vitro or ex vivo as a carrier for produced bone tissue, or for producing a bone graft.

EFFECT: group of inventions provides bone tissue regeneration.

24 cl, 10 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to ophthalmology, and can be applied for cell therapy in case of different ophthalmopathologies, accompanied by dystrophic and atrophic processes as well. Three-component complex for cell therapy contains mesenchymal stem cells, labeled by magnetic microparticles. Cells are translocated into biological or synthetic fine-pore material, which in its turn is strongly fastened with polymer magnetic material with induction of constant magnetic field 1.5 mT, with multipolar reverse magnetisation.

EFFECT: invention ensures directed supply of stem cells to pathological nidus and holding stem cells for specified time with creation of possibility of giving complex any form, size and space configuration, suitable for extrascleral implantation to any area of eyeball or visual.

2 cl, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to ophthalmology, and can be used for treatment of optic nerve atrophy of different etiology. Tree-component complex is implanted to patient in such a way that it covers optic nerve, posterior short ciliary arteries and part of retrobulbar cellular tissue, without joining them. Three-component complex contains mesenchymal stem cells, labeled with magnetic microparticles. Cells are transposed into biological or synthetic fine-porous material, which is tightly connected with polymer magnetic material with induction of constant magnetic field 1.5 mT, with multi-polar reversible magnetisation.

EFFECT: invention ensures improvement or stable stabilisation of visual functions, extension of vision field boundaries, acceleration of hemodynamics in retina and optic nerve.

2 cl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to ophthalmology, and can be used for surgical treatment of progressing and complicated myopia. As scleroplastic material implanted is three-component complex, which contains mesenchymal stem cells, labeled with magnetic microparticles. Cells are translocated into biological or synthetic fine-porous material, which is tightly connected with polymer magnetic material with induction of constant magnetic field 1.5 mT, with multi-polar reversible magnetisation.

EFFECT: invention ensures enhancement of strength-elastic properties of sclera, stabilisation of myopic process with simultaneous prevention of development of dystrophic changes of eye fundus or further progressing in case of their presence.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, and concerns a method for preparing a drug preparation of an immunomodulator for severe purulent-septic and autoimmune diseases on the basis of a peptide fraction recovered from mammalian spleen tissue or cells (particularly swine or cattle spleen). Substance of the invention: there are mixed biologically active substance - that is a peptide fraction recovered from mammalian spleen tissue or cells with a substance preventing protein molecule coagulation, and an antibiotic. Gelofusine is used as the substance preventing protein molecule coagulation.

EFFECT: invention provides the high therapeutic effect in preventing and treating the purulent-septic and autoimmune diseases.

1 dwg, 1 ex, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely a blood polymer for the regeneration of injured tissue or defect osseous or chondral structures. The blood polymer for the regeneration of injured tissue or defect osseous or chondral structures containing: blood, blood plasma or thrombocyte concentrate, erythropoietin (EPO), stem cells or marrow cells, wherein the blood polymer is prepared by mixing the respective ingredients taken in the liquid state, and the polymerisation is ensured by a gelling material specified in calcium ions, thrombin, protamine, prothrombin, fibrin or the extra-cellular matrix ingredients of a biological nature. The method for the regeneration of injured tissue or defect osseous or chondral structures in an individual.

EFFECT: polymer enables the faster and better regeneration of injured and defect tissues.

8 cl, 12 ex

FIELD: medicine.

SUBSTANCE: with underlying conventional treatment, a leukocyte serum preparation is used that is produced by incubation of 20-30 ml of a patient's whole blood bottled in three sealed flasks in a thermostat at a temperature of 37-38°C for 24, 48 and 66-68 hours respectively; then the flasks are removed from the thermostat; the leukocyte serum is aspirated by a sterile syringe; the leukocyte serum preparation prepared at different times is introduced into the patient three times subcutaneously in a dose of 2-5 ml daily or triduan.

EFFECT: method provides higher clinical effectiveness and reduced length of treatment.

2 tbl, 1 ex

Up!